Groen, Richard W.J.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 521

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology

Monoclonal and Polyclonal Antibodies ResearchMultiple Myeloma Research and Treatments

Cited by 297

Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia

Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., et al. (2014) · Journal of Clinical Investigation

Acute Lymphoblastic Leukemia researchProtein Tyrosine Phosphatases

Cited by 220

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 151

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

Katsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., et al. (2021) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 131

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 123

Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138

van der Schans, J. J., Wang, Z., van Arkel, J., van Schaik, T., Katsarou, A., Ruiter, R., Baardemans, T., Yuan, H., de Bruijn, J., Zweegman, S., et al. (2023) · Clinical Cancer Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 17

Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2

Pastoors, D., Havermans, M., Mulet-Lazaro, R., Brian, D., Noort, W., Grasel, J., Hoogenboezem, R., Smeenk, L., Demmers, J. A. A., Milsom, M. D., et al. (2024) · Science Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 15